1. Home
  2. ATCX vs NEUP Comparison

ATCX vs NEUP Comparison

Compare ATCX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlas Critical Minerals Corporation Common Stock

ATCX

Atlas Critical Minerals Corporation Common Stock

N/A

Current Price

$3.90

Market Cap

20.0M

Sector

N/A

ML Signal

N/A

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.57

Market Cap

23.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATCX
NEUP
Founded
2016
1996
Country
Brazil
United States
Employees
13
8
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
20.0M
23.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ATCX
NEUP
Price
$3.90
$4.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$13.75
$21.00
AVG Volume (30 Days)
16.8K
60.8K
Earning Date
03-16-2023
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$827,667.00
N/A
Revenue Next Year
$166.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.50
$3.65
52 Week High
$14.01
$21.31

Technical Indicators

Market Signals
Indicator
ATCX
NEUP
Relative Strength Index (RSI) 41.43 48.06
Support Level $3.50 $3.91
Resistance Level $5.62 $5.06
Average True Range (ATR) 0.36 0.29
MACD 0.04 0.01
Stochastic Oscillator 45.65 62.01

Price Performance

Historical Comparison
ATCX
NEUP

About ATCX Atlas Critical Minerals Corporation Common Stock

Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: